• 1
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366
  • 2
    Konety BR, Joyce CF, Wise M. Bladder cancer. In LitwinMS, SaigalCS eds, Urologic Diseases in America, Chapt. 7.Washington, DC: Government Publishing Office, 2007: 22380
  • 3
    Ries LA, Harkins D, Krapcho M et al. SEER, Cancer Statistics Review, 1975–2003. National Cancer Institute Bethesda, MD. Available at:, based on November 2005 SEER data submission, posted to the SEER web site, 2006. Accessed March 2008
  • 4
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organisation/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 143548
  • 5
    Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6: 67886
  • 6
    Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004; 3: 1647
  • 7
    Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003; 89: 27
  • 8
    Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int 2007; 71: 10315
  • 9
    Ivanov S, Liao SY, Ivanova A et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158: 90519
  • 10
    Trastour C, Benizri E, Ettore F et al. HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007; 120: 14518
  • 11
    Loncaster JA, Harris AL, Davidson SE et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 63949
  • 12
    Lee S, Shin HJ, Han IO et al. Tumour carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Sci 2007; 98: 32933
  • 13
    Swinson DE, Jones JL, Richardson D et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumour hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003; 21: 47382
  • 14
    Maseide K, Kandel RA, Bell RS et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004; 10: 446471
  • 15
    Driessen A, Landuyt W, Pastorekova S et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006; 243: 33440
  • 16
    Chen J, Röcken C, Hoffmann J et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005; 54: 9207
  • 17
    Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 371421
  • 18
    Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 80211
  • 19
    Turner KJ, Crew JP, Wykoff CC et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 2002; 86: 127682
  • 20
    Klatte T, Seligson DB, Leppert JT et al. Carbonic anhydrase IX (CAIX) in bladder cancer: a diagnostic, prognostic and therapeutic molecular marker. J Urol 2007; 77: 79 (Abstract 236)
  • 21
    Sherwood BT, Colquhoun AJ, Richardson D et al. Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. Clin Oncol (R Coll Radiol) 2007; 19: 77783
  • 22
    Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003; 89: 12907
  • 23
    Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res 2000; 60: 707583
  • 24
    Ord JJ, Streeter EH, Roberts IS, Cranston D, Harris AL. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br J Cancer 2005; 93: 34654
  • 25
    Ord JJ, Agrawal S, Thamboo TP et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 2007; 178: 67782
  • 26
    Hussain SA, Palmer DH, Ganesan R et al. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 2004; 11: 100510
  • 27
    Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 5762
  • 28
    Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7: 10915
  • 29
    Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006; 33: 57682
  • 30
    Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett 2007; 255: 23240
  • 31
    Uemura H, Fujimoto K, Tanaka M et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12: 176875
  • 32
    Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother (1997) 2007; 30: 11622
  • 33
    Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol Immunother 2007; 56: 1097105